|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tangen CM, Hussain MH, Higano CS,
Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF,
Crawford ED, Vogelzang NJ, et al: Improved overall survival trends
of men with newly diagnosed M1 prostate cancer: A SWOG phase III
trial experience (S8494, S8894 and S9346). J Urol. 188:1164–1169.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Valenca LB, Sweeney CJ and Pomerantz MM:
Sequencing current therapies in the treatment of metastatic
prostate cancer. Cancer Treat Rev. 41:332–340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chapin BF, Mcguire SE and Aparicio A: Is
treatment of the primary tumor in metastatic prostate cancer
justified? Eur Urol. 65:1067–1068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Culp SH, Schellhammer PF and Williams MB:
Might men diagnosed with metastatic prostate cancer benefit from
definitive treatment of the primary tumor? A SEER-based study. Eur
Urol. 65:1058–1066. 2014. View Article : Google Scholar
|
|
6
|
Swanson G, Thompson I, Basler J and
Crawford ED: Metastatic prostate cancer - Does treatment of the
primary tumor matter? J Urol. 176:1292–1298. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qin XJ, Ma CG, Ye DW, Yao XD, Zhang SL,
Dai B, Zhang HL, Shen YJ, Zhu Y, Zhu YP, et al: Tumor cytoreduction
results in better response to androgen ablation - a preliminary
report of palliative transurethral resection of the prostate in
metastatic hormone sensitive prostate cancer. Urol Oncol.
30:145–149. 2012. View Article : Google Scholar
|
|
8
|
Nguyen DX: Tracing the origins of
metastasis. J Pathol. 223:195–204. 2011. View Article : Google Scholar
|
|
9
|
Miyamoto DT, Sequist LV and Lee RJ:
Circulating tumour cells - monitoring treatment response in
prostate cancer. Nat Rev Clin Oncol. 11:401–412. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sceneay J, Smyth MJ and Möller A: The
pre-metastatic niche: Finding common ground. Cancer Metastasis Rev.
32:449–464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kaplan RN, Riba RD, Zacharoulis S, Bramley
AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et
al: VEGFR1-positive haematopoietic bone marrow progenitors initiate
the pre-metastatic niche. Nature. 438:820–827. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu C, Shiozawa Y, Taichman RS, McCauley
LK, Pienta K and Keller E: Prostate cancer and parasitism of the
bone hematopoietic stem cell niche. Crit Rev Eukaryot Gene Expr.
22:131–148. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hüsemann Y, Geigl JB, Schubert F, Musiani
P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, et
al: Systemic spread is an early step in breast cancer. Cancer Cell.
13:58–68. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Morgan SC and Parker CC: Local treatment
of metastatic cancer - killing the seed or disturbing the soil? Nat
Rev Clin Oncol. 8:504–506. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cifuentes FF, Valenzuela RH, Contreras HR
and Castellón EA: Development of an orthotopic model of human
metastatic prostate cancer in the NOD-SCIDγ mouse (Mus musculus)
anterior prostate. Oncol Lett. 10:2142–2148. 2015.
|
|
16
|
Demicheli R, Retsky MW, Hrushesky WJ, Baum
M and Gukas ID: The effects of surgery on tumor growth: A century
of investigations. Ann Oncol. 19:1821–1828. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Clamage DM, Sanford CS, Vander AJ and Mouw
DR: Effects of psychosocial stimuli on plasma renin activity in
rats. Am J Physiol. 231:1290–1294. 1976.PubMed/NCBI
|
|
18
|
Fisher B, Gunduz N, Coyle J, Rudock C and
Saffer E: Presence of a growth-stimulating factor in serum
following primary tumor removal in mice. Cancer Res. 49:1996–2001.
1989.PubMed/NCBI
|
|
19
|
Camphausen K, Moses MA, Beecken WD, Khan
MK, Folkman J and O'Reilly MS: Radiation therapy to a primary tumor
accelerates metastatic growth in mice. Cancer Res. 61:2207–2211.
2001.PubMed/NCBI
|
|
20
|
Aguirre-Ghiso JA: Models, mechanisms and
clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Giancotti FG: Mechanisms governing
metastatic dormancy and reactivation. Cell. 155:750–764. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peinado H, Lavotshkin S and Lyden D: The
secreted factors responsible for pre-metastatic niche formation:
Old sayings and new thoughts. Semin Cancer Biol. 21:139–146. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ghajar CM, Peinado H, Mori H, Matei IR,
Evason KJ, Brazier H, Almeida D, Koller A, Hajjar KA, Stainier DY,
et al: The perivascular niche regulates breast tumour dormancy. Nat
Cell Biol. 15:807–817. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Antonyak MA and Cerione RA: Microvesicles
as mediators of intercellular communication in cancer. Methods Mol
Biol. 1165:147–173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uppal A, Ferguson MK, Posner MC, Hellman
S, Khodarev NN and Weichselbaum RR: Towards a molecular basis of
oligometastatic disease: Potential role of micro-RNAs. Clin Exp
Metastasis. 31:735–748. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tu SM and Lin SH: Prostate cancer stem
cells. Clin Genitourin Cancer. 10:69–76. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shackleton M, Quintana E, Fearon ER and
Morrison SJ: Heterogeneity in cancer: Cancer stem cells versus
clonal evolution. Cell. 138:822–829. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ben-Eliyahu S: The promotion of tumor
metastasis by surgery and stress: Immunological basis and
implications for psychoneuroimmunology. Brain Behav Immun. 17(Suppl
1): S27–S36. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Neeman E and Ben-Eliyahu S: Surgery and
stress promote cancer metastasis: New outlooks on perioperative
mediating mechanisms and immune involvement. Brain Behav Immun.
30(Suppl): S32–S40. 2013. View Article : Google Scholar
|
|
30
|
Shultz LD, Goodwin N, Ishikawa F, Hosur V,
Lyons BL and Greiner DL: Human cancer growth and therapy in
immunodeficient mouse models. Cold Spring Harb Protoc.
2014:694–708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Narasimhulu DM, Khoury-Collado F and Chi
DS: Radical surgery in ovarian cancer. Curr Oncol Rep. 17:162015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Faiena I, Singer EA, Pumill C and Kim IY:
Cytoreductive prostatectomy: Evidence in support of a new surgical
paradigm (Review). Int J Oncol. 45:2193–2198. 2014.PubMed/NCBI
|
|
33
|
Krabbe LM, Haddad AQ, Westerman ME and
Margulis V: Surgical management of metastatic renal cell carcinoma
in the era of targeted therapies. World J Urol. 32:615–622. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Neuman HB, Morrogh M, Gonen M, Van Zee KJ,
Morrow M and King TA: Stage IV breast cancer in the era of targeted
therapy: Does surgery of the primary tumor matter? Cancer.
116:1226–1233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Verhagen PC, Schröder FH, Collette L and
Bangma CH: Does local treatment of the prostate in advanced and/or
lymph node metastatic disease improve efficacy of
androgen-deprivation therapy? A systematic review. Eur Urol.
58:261–269. 2010. View Article : Google Scholar : PubMed/NCBI
|
